Skip to main content
. 2022 Jun 30;13:909821. doi: 10.3389/fphar.2022.909821

TABLE 1.

Role of ferroptosis in drug resistance and the strategy to overcome treatment resistance in cancer.

Treatment strategy Treatment Cancer type Strategy to overcome resistance References
Chemotherapy Cisplatin Head and neck cancer CDDP + erastin and sulfasalazine Roh et al. (2016)
Head and neck cancer CDDP + Artesunate Roh et al. (2017)
Osteosarcoma CDDP + Erastin and RSL3 Liu and Wang (2019)
Ovarian cancer CDDP + Erastin Li et al. (2020)
Gastric cancer CDDP + Erastin Haiyang Zhang et al. (2020)
Non-small-cell lung cancer CDDP + RSL3 Deng et al. (2021)
Gastric cancer CDDP + erastin RSL3 or antagonist liproxstatin-1 Dazhi Fu et al. (2021)
Subcutaneous tumor CDDP+11β-hydroxy-ent-16-kaurene-15-one Yong Sun et al. (2021)
Pancreatic adenocarcinoma CDDP + gemcitabine Wei et al. (2022)
Ovarian cancer CDDP + mTOR inhibitor Hua-Wen Li et al. (2022)
Triple-negative breast cancer CDDP + HLF-knockdown Hengyu Li et al. (2022)
Oxaliplatin Colorectal cancer Oxaliplatin + RSL3 Changshun Yang et al. (2021)
Colorectal cancer Oxaliplatin + GPX4 inhibitor Changshun Yang et al. (2021)
Platinum Non-small-cell lung cancer Platinum + GPX4 inhibitor Wenwen Liu et al. (2021)
Chemotherapy Docetaxel Ovarian cancer Erastin + Docetaxel Zhou et al. (2019)
Paclitaxel Uterine serous carcinoma Paclitaxel + Sulfasalazine Sugiyama et al. (2020)
Gemcitabine Pancreatic cancer ARF6 abrogation Zeng Ye et al. (2020)
Pancreatic cancer Gemcitabine + RSL3 Tang et al. (2020)
5-fluorouracil Colorectal cancer Gemcitabine + Ferroptosis inducer Chaudhary et al. (2021)
Temozolomide Glioblastoma Temozolomide + ALZ003 upregulation Xin Chen et al. (2020)
Targeted therapy Sunitinib Renal cell carcinoma Sunitinib + Artesunate Markowitsch et al. (2020)
Sorafenib Hepatocellular carcinoma Sorafenib + Metallothionein (MT)-1G inhibition Sun et al. (2016)
Gastric cancer Sorafenib + Sirtuins 6 inhibition Cai et al. (2021)
Hepatocellular carcinoma Sorafenib + ABCC5 inhibition Huang et al. (2021)
Hepatocellular carcinoma Sorafenib + Targeting YAP/TAZ or ATF4 Gao et al. (2021)
Targeted therapy Gefitinib Non-small-cell lung cancer Gefitinib + GPX4 inhibition Viswanathan et al. (2017)
Cetuximab (anti-EGFR antibody) Colorectal cancer Cetuximab + Vitamin C Lorenzato et al. (2020)
EGFR-TKIs EGFR-activating mutant lung adenocarcinoma EGFR-TKIs + Vorinostat Zhang et al. (2021)
Androgen Receptor inhibitors Prostate cancer Androgen Receptor inhibitors +2,4-dienoyl-CoA reductase (DECR1) Blomme et al. (2020)
Prostate cancer Androgen Receptor inhibitors + GPX4 inhibition Tousignant et al. (2020)
Prostate cancer Androgen Receptor inhibitors +2,4-dienoyl-CoA reductase (DECR1) Nassar et al. (2020)
BRAF inhibitor Melanoma BRAF inhibition + Target SREBF2 Hong et al. (2021)
Vemurafenib Melanoma Vemurafenib + Ferroptosis-inducing drugs  Tsoi et al. (2018)
Abemaciclib, Sorafenib Hepatocellular carcinoma Sorafenib + PSTK inhibition Chen et al. (2022)
Lapatinib Non-small-cell lung cancer Lapatinib + GPX4 inhibition Ni et al. (2021)
Multi-drug Multi-drug resistance Drug-resistant Breast Cancer Cells Basic therapy + Pt-AuNS prodrugs Del Valle et al. (2020)
Multi-drug Multi-drug resistance Various sensitive and drug-resistant phenotypes Standard treatment + Ardisiacrispin B Mbaveng et al. (2018b)
Various sensitive and drug-resistant cell lines Basic therapy + Epunctanone Mbaveng et al. (2018a)
Various sensitive and drug-resistant cell lines (leukemia cells) Basic therapy + Ungeremine Mbaveng et al. (2019)
Multiple drugs Lapatinib, Erlotinib Breast cancer, Non-small-cell lung cancer, ovarian cancer, melanoma Standard treatment + GPX4 inhibition Hangauer et al. (2017)
Carboplatin, Paclitaxel, Vemurafenib, Dabrafenib, Trametinib, Dabrafenib
Immunotherapy Anti-PD-1/PD-L1 blockade Mammary carcinoma Anti-PD-1/PD-L1 blockade + TYRO3 inhibition Zhou Jiang et al. (2021)
Bladder cancer Anti-PD-1/PD-L1 blockade + ACSL4activation Liao et al. (2022)
Radiotherapy Radiation Clinically relevant radioresistant (CRR) cells Basic therapy + miR-7-5p knockdown Tomita et al. (2021)
Lung cancer, fibrosarcoma cell, breast adenocarcinoma cell Ionizing radiation + Ferroptosis inducers Lei et al. (2020)